Integrated Single-Cell Chromatin And Transcriptomic Analyses Of Peripheral Immune Cells In Patients With Alopecia Areata
July 2025
in “
Frontiers in Immunology
”
Research cited in this study
17 / 17 results
research European Expert Consensus Statement on the Systemic Treatment of Alopecia Areata
Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
research Inhibition of T-Cell Activity in Alopecia Areata: Recent Developments and New Directions
New treatments targeting T-cell pathways are needed for better alopecia areata management.
research A Case of Atopic Dermatitis with Self-Healing Acute Diffuse and Total Alopecia During Nemolizumab Treatment
research Markers of Venous Thromboembolism Risk in Patients with Alopecia Areata: Is There Anything to Worry About?
People with alopecia areata may have a higher risk of blood clots.
research A Novel Predictive Model for the Recurrence of Pediatric Alopecia Areata by Bioinformatics Analysis and a Single-Center Prospective Study
A new model uses specific blood markers to predict if children's hair loss will return.
research Differential Impact of Environmental Factors on Systemic and Localized Autoimmunity
Environmental factors like diet and vitamin levels, especially Vitamin D, can affect autoimmune diseases differently, with lifestyle changes potentially improving outcomes.
research Construction of Regulatory Network for Alopecia Areata Progression and Identification of Immune Monitoring Genes Based on Multiple Machine-Learning Algorithms
Researchers found four genes that could help diagnose severe alopecia areata early.
research Ex Vivo Treatment with Allogenic Mesenchymal Stem Cells on Peripheral Blood Mononuclear Cells of Patients with Severe Alopecia Areata
Using healthy donor stem cells can potentially calm overactive immune cells and reduce inflammation in severe hair loss patients, offering a possible treatment method.
research Hair Follicle Immune Privilege and Its Collapse in Alopecia Areata
Hair follicles are normally protected from the immune system, but when this protection fails, it can cause hair loss in alopecia areata.
research An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
Tofacitinib may help treat severe hair loss, but more research is needed.
research Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata
Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
research Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata
Ruxolitinib effectively regrows hair in most patients with severe hair loss.
research Alopecia Areata Profiling Shows TH1, TH2, and IL-23 Cytokine Activation Without Parallel TH17/TH22 Skewing
Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.
research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition
Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
research Maintenance of Hair Follicle Immune Privilege Is Linked to Prevention of NK Cell Attack
Hair follicles prevent NK cell attacks to avoid hair loss.
research The Role of Sebaceous Gland Activity and Scalp Microfloral Metabolism in the Etiology of Seborrheic Dermatitis and Dandruff
Dandruff and seborrheic dermatitis are caused by yeast feeding on scalp oils, leading to irritation and flaking.
research Apoptosis Resistance in Peripheral Blood Lymphocytes of Alopecia Areata Patients
Alopecia areata patients have more activated T cells in their blood, which may help in developing treatments.